Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00063687
Recruitment Status : Completed
First Posted : July 3, 2003
Last Update Posted : August 5, 2005
Information provided by:
Cardiome Pharma

Brief Summary:
The OPT-CHF (OxyPurinol Therapy for CHF) study is designed to demonstrate the efficacy and safety of oral oxypurinol vs. placebo in a randomized, double-blind, twenty-four week trial in 400 patients in up to 50 centers. Measures of clinical efficacy (NYHA class and Patient Global Assessment) as well as clinical outcomes (e.g., death, worsening heart failure, and hospitalization) will be assessed as a composite endpoint in this trial.

Condition or disease Intervention/treatment Phase
Congestive Heart Failure Drug: Oxypurinol Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients With NYHA Class III-IV Congestive Heart Failure
Study Start Date : March 2003
Study Completion Date : June 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • 18-85 years old,
  • Stable NYHA Class III-IV
  • Hospitalization or ER visits in past 18 months for worsening Heart Failure (or addition of new heart failure medication added to regimen due to lack of stability on current regimen.
  • EF =< 40%

Exclusion criteria

  • Any condition (other than CHF) that could limit exercise
  • Any concurrent disease likely to limit life expectancy.
  • Participation in another clinical trial
  • Primary valvular disease, active myocarditis, or an obstructive or restrictive cardio-myopathy
  • Heart Attack, Stroke, Unstable Angina or Cardiac surgery within previous 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00063687

United States, California
Carr-Dzindzio Cardiology
Oceanside, California, United States, 92056
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Boston Medical Center
Boston, Massachusetts, United States, 02118
United States, New York
Saint Vincents Hospital and Medical Center
New York, New York, United States, 10011
Sponsors and Collaborators
Cardiome Pharma
Principal Investigator: Joshua Hare, MD Johns Hopkins University

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00063687     History of Changes
Other Study ID Numbers: 500-02-01
First Posted: July 3, 2003    Key Record Dates
Last Update Posted: August 5, 2005
Last Verified: July 2003

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action